Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
72 |
Employees |
- |
Revenues (TTM) (Millions $) |
21 |
Net Income (TTM) (Millions $) |
-110 |
Cash Flow (TTM) (Millions $) |
20 |
Capital Exp. (TTM) (Millions $) |
2 |
Savient Pharmaceuticals Inc
Savient Pharmaceuticals Inc was a biopharmaceutical company that developed and commercialized innovative therapies for unmet medical needs. The company focused on developing treatments for patients with severe gout, a painful inflammatory condition. Their flagship product was called Krystexxa, which was approved by the U.S. Food and Drug Administration for the treatment of refractory chronic gout. Savient Pharmaceuticals aimed to improve the lives of patients suffering from these debilitating conditions by offering effective and long-lasting treatments. However, the company faced financial difficulties and eventually filed for bankruptcy in 2013.
|